Abstract
Pre-clinical characterization of novel substituted pyrrolidines that are high affinity histamine H(3) receptor antagonists is described. These compounds efficiently penetrate the CNS and occupy the histamine H(3) receptor in rat brain following oral administration. One compound, (2S,4R)-1-[2-(4-cyclobutyl-[1,4]diazepane-1-carbonyl)-4-(3-fluoro-phenoxy)-pyrrolidin-1-yl]-ethanone, was extensively profiled and shows promise as a potential clinical candidate.
2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Azepines / chemical synthesis
-
Azepines / chemistry*
-
Azepines / pharmacokinetics
-
Brain / metabolism
-
Dogs
-
Drug Evaluation, Preclinical
-
Histamine H3 Antagonists / chemical synthesis
-
Histamine H3 Antagonists / chemistry*
-
Histamine H3 Antagonists / pharmacokinetics
-
Humans
-
Mice
-
Pyrrolidines / chemical synthesis
-
Pyrrolidines / chemistry*
-
Pyrrolidines / pharmacokinetics
-
Rats
-
Receptors, Histamine H3 / chemistry*
-
Receptors, Histamine H3 / metabolism
-
Structure-Activity Relationship
Substances
-
1-(2-(4-cyclobutyl-(1,4)diazepane-1-carbonyl)-4-(3-fluorophenoxy)pyrrolidin-1-yl)ethanone
-
Azepines
-
Histamine H3 Antagonists
-
Pyrrolidines
-
Receptors, Histamine H3